Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

Endocarditis IV: Nursing Management

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...

Endocarditis III: Medical Management

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

Kidney Transplant III: Nursing Management

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A transfusion prescription template and other human factor interventions to improve balanced transfusion delivery in major haemorrhage due to trauma.

Transfusion medicine (Oxford, England)·2018

Same author

Variant CJD and blood transfusion.

Vox sanguinis·2015

Same author

Cardiopulmonary exercise testing before and after blood transfusion: a prospective clinical study.

British journal of anaesthesia·2014

Same author

Pre-transfusion compatibility guidelines: a new edition.

Transfusion medicine (Oxford, England)·2013

Same author

Transfusion practice.

Transfusion medicine (Oxford, England)·2009

Same author

Progress in TRALI.

Transfusion medicine (Oxford, England)·2008

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Strategies to reduce transfusion acquired vCJD.

¹Department of Haematology, Freeman Hospital, Newcastle upon Tyne, UK. Jonathan.Wallis@nuth.nhs.uk

Transfusion Medicine (Oxford, England)

|November 13, 2010

Summary

Variant Creutzfeldt-Jakob disease (vCJD) poses a transfusion risk. Targeting low-risk donors for blood components like fresh frozen plasma (FFP) can prevent transfusion-acquired vCJD cases with minimal cost.

Area of Science:

Transfusion Medicine
Epidemiology
Neurology

Background:

Variant Creutzfeldt-Jakob disease (vCJD) is transmissible via blood transfusion.
The risk of transfusion-transmitted vCJD is linked to the prevalence of infected donors.

Purpose of the Study:

To estimate the potential number of transfusion-acquired vCJD cases in a less susceptible population.
To evaluate strategies for preventing transfusion-acquired vCJD, including plasma importation and donor selection.

Main Methods:

Epidemiological modeling based on current vCJD epidemic data.
Risk assessment for transfusion-acquired vCJD.
Cost-benefit analysis of plasma importation versus targeted donor selection.

Main Results:

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Related Experiment Videos

Last Updated: Jun 6, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

A maximum of 300 additional vCJD cases may occur in a less susceptible population.
A maximum of one transfusion-acquired vCJD case is predicted within 3 years from plasma transfusion.
Plasma importation is estimated to cost £30 million annually.

Conclusions:

Targeting low-risk donors for blood component production (e.g., fresh frozen plasma, platelets) is a cost-effective alternative to plasma importation.
This strategy can significantly reduce the incidence of transfusion-acquired vCJD without substantial additional healthcare costs.